The latest price target for ACADIA Pharmaceuticals (NASDAQ:ACAD) was reported by Citigroup on January 6, 2026. The analyst firm set a price target for $36.00 expecting ACAD to rise to within 12 months (a possible 33.98% upside). 48 analyst firms have reported ratings in the last year.

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) was provided by Citigroup, and ACADIA Pharmaceuticals maintained their buy rating.

The last upgrade for ACADIA Pharmaceuticals Inc happened on May 21, 2025 when Deutsche Bank raised their price target to $35. Deutsche Bank previously had a hold for ACADIA Pharmaceuticals Inc.

The last downgrade for ACADIA Pharmaceuticals Inc happened on January 3, 2025 when Guggenheim changed their price target from $23 to $20 for ACADIA Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on January 6, 2026 so you should expect the next rating to be made available sometime around January 6, 2027.

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a maintained with a price target of $33.00 to $36.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $26.87, which is out of the analyst’s predicted range.